Retractable Technologies Inc
RVP0.829USD
+0.005+0.64%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
24.80MMarket Cap
LossP/E TTM
More Details of Retractable Technologies Inc Company
Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors.
Retractable Technologies Inc Info
Ticker SymbolRVP
Company nameRetractable Technologies Inc
IPO dateMay 04, 2001
CEOShaw (Thomas J)
Number of employees221
Security typeOrdinary Share
Fiscal year-endMay 04
Address511 Lobo Lane
CityLITTLE ELM
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code75068-0009
Phone19722941010
Websitehttps://retractable.com/
Ticker SymbolRVP
IPO dateMay 04, 2001
CEOShaw (Thomas J)
Company Executives of Retractable Technologies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Shaw
Mr. Thomas J. Shaw
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
16.33M
+0.08%
Mr. Marco Laterza, CPA
Mr. Marco Laterza, CPA
Independent Director
Independent Director
85.00K
--
Mr. Darren E. Findley
Mr. Darren E. Findley
Independent Director
Independent Director
4.20K
--
Mr. John W. Fort, III
Mr. John W. Fort, III
Chief Financial Officer, Vice President, Treasurer, Director
Chief Financial Officer, Vice President, Treasurer, Director
--
--
Ms. Michele M. Larios, J.D.
Ms. Michele M. Larios, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Mr. Walter O. Bigby, Jr.
Mr. Walter O. Bigby, Jr.
Independent Director
Independent Director
--
--
Ms. Amy Mack
Ms. Amy Mack
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Shaw
Mr. Thomas J. Shaw
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
16.33M
+0.08%
Mr. Marco Laterza, CPA
Mr. Marco Laterza, CPA
Independent Director
Independent Director
85.00K
--
Mr. Darren E. Findley
Mr. Darren E. Findley
Independent Director
Independent Director
4.20K
--
Mr. John W. Fort, III
Mr. John W. Fort, III
Chief Financial Officer, Vice President, Treasurer, Director
Chief Financial Officer, Vice President, Treasurer, Director
--
--
Ms. Michele M. Larios, J.D.
Ms. Michele M. Larios, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Mr. Walter O. Bigby, Jr.
Mr. Walter O. Bigby, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Syringes
5.93M
56.76%
EasyPoint Needles
4.20M
40.16%
Blood Cllection Products
302.78K
2.90%
Other Products
19.13K
0.18%
By RegionUSD
Name
Revenue
Proportion
United States
8.49M
81.27%
North and South America(excluding U.S)
1.75M
16.71%
Other International
210.62K
2.02%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Syringes
5.93M
56.76%
EasyPoint Needles
4.20M
40.16%
Blood Cllection Products
302.78K
2.90%
Other Products
19.13K
0.18%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shaw (Thomas J)
54.55%
Larios Michele Mitchell
2.88%
The Vanguard Group, Inc.
2.25%
Renaissance Technologies LLC
1.43%
Eversept Partners, LP
1.21%
Other
37.68%
Shareholders
Shareholders
Proportion
Shaw (Thomas J)
54.55%
Larios Michele Mitchell
2.88%
The Vanguard Group, Inc.
2.25%
Renaissance Technologies LLC
1.43%
Eversept Partners, LP
1.21%
Other
37.68%
Shareholder Types
Shareholders
Proportion
Individual Investor
58.12%
Investment Advisor
4.16%
Hedge Fund
3.07%
Investment Advisor/Hedge Fund
0.92%
Venture Capital
0.05%
Research Firm
0.04%
Other
33.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
63
2.10M
7.00%
-941.15K
2025Q2
76
19.64M
65.62%
-749.70K
2025Q1
78
19.36M
64.67%
-761.97K
2024Q4
83
19.19M
64.11%
-1.01M
2024Q3
90
19.53M
65.24%
-827.36K
2024Q2
106
19.17M
64.04%
-1.44M
2024Q1
142
19.01M
63.51%
-2.11M
2023Q4
155
19.23M
64.23%
-1.87M
2023Q3
169
20.44M
68.26%
-2.39M
2023Q2
184
20.87M
69.70%
-2.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shaw (Thomas J)
16.18M
54.04%
+33.50K
+0.21%
Sep 29, 2025
Larios Michele Mitchell
861.00K
2.88%
--
--
Mar 10, 2025
The Vanguard Group, Inc.
673.81K
2.25%
-15.70K
-2.28%
Jun 30, 2025
Renaissance Technologies LLC
348.41K
1.16%
-11.24K
-3.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
245.16K
0.82%
-26.39K
-9.72%
Jun 30, 2025
Geode Capital Management, L.L.C.
128.11K
0.43%
-143.00
-0.11%
Jun 30, 2025
Bridgeway Capital Management, LLC
155.63K
0.52%
--
--
Jun 30, 2025
Laterza (Marco)
85.00K
0.28%
--
--
Mar 10, 2025
Bigby (Walter O Jr)
80.00K
0.27%
--
--
Mar 10, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Retractable Technologies Inc?
The top five shareholders of Retractable Technologies Inc are:
Shaw (Thomas J) holds 16.18M shares, accounting for 54.04% of the total shares.
Larios Michele Mitchell holds 861.00K shares, accounting for 2.88% of the total shares.
The Vanguard Group, Inc. holds 673.81K shares, accounting for 2.25% of the total shares.
Renaissance Technologies LLC holds 348.41K shares, accounting for 1.16% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 245.16K shares, accounting for 0.82% of the total shares.
Shaw (Thomas J) holds 16.18M shares, accounting for 54.04% of the total shares.
Larios Michele Mitchell holds 861.00K shares, accounting for 2.88% of the total shares.
The Vanguard Group, Inc. holds 673.81K shares, accounting for 2.25% of the total shares.
Renaissance Technologies LLC holds 348.41K shares, accounting for 1.16% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 245.16K shares, accounting for 0.82% of the total shares.
What are the top three shareholder types of Retractable Technologies Inc?
The top three shareholder types of Retractable Technologies Inc are:
Shaw (Thomas J)
Larios Michele Mitchell
The Vanguard Group, Inc.
Shaw (Thomas J)
Larios Michele Mitchell
The Vanguard Group, Inc.
How many institutions hold shares of Retractable Technologies Inc (RVP)?
As of 2025Q3, 63 institutions hold shares of Retractable Technologies Inc, with a combined market value of approximately 2.10M, accounting for 7.00% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -58.62%.
What is the biggest source of revenue for Retractable Technologies Inc?
In FY2025Q2, the Syringes business generated the highest revenue for Retractable Technologies Inc, amounting to 5.93M and accounting for 56.76% of total revenue.
